{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"64"}],"units":"Participants"}],"description":"Number of participants experiencing any grade treatment-emergent neuropathic pain events based on CTCAEv3 as reported on case report forms.","groups":[{"description":"Participants received intravenous bortezomib on a 3-week dosing cycle: 1.3 mg/m2 on days 1, 4, 8 and 11 followed by 10 day rest period for up to 8 cycles or for 2 cycles beyond complete response. Participants with progressive disease or unacceptable toxicity discontinued treatment.","id":"OG000","title":"Bortezomib"}],"paramType":"NUMBER","populationDescription":"The analysis population is comprised of eligible and treated participants.","reportingStatus":"POSTED","timeFrame":"Assessed each cycle throughout treatment from time of first dose and up to day 30 post-treatment. Treatment duration in months was a median (range) of 5.1 (0.8-6.1).","title":"Number of Participants With Treatment-Emergent Neuropathic Pain","type":"SECONDARY","unitOfMeasure":"participants"}